Clinical Drug Investigation

, Volume 30, Issue 6, pp 351–364 | Cite as

Safety and Tolerability of a New Formulation of Pancrelipase Delayed-Release Capsules (CREON®) in Children Under Seven Years of Age with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis

An Open-Label, Multicentre, Single-Treatment-Arm Study
  • Gavin R. Graff
  • John McNamara
  • James Royall
  • Steven Caras
  • Kristin Forssmann
Original Research Article


Background: Exocrine pancreatic insufficiency (EPI) is a deficiency of digestive enzymes caused by diseases such as cystic fibrosis (CF). Patients with EPI due to CF require pancreatic enzyme replacement therapy (PERT) in order to maintain adequate nutrition. A new formulation of pancrelipase delayed-release capsules (CREON®) recently received US FDA approval and has demonstrated efficacy and safety in patients with CF aged ≥7 years.

Objectives: The objectives of this study were to observe the safety and tolerability of new formulation pancrelipase delayed-release capsules (study drug) versus the standard of care PERT (standard therapy) in children aged <7 years with CF and EPI. Secondary objectives were to assess the ease of accurate dosing of study drug, monitor clinical symptoms and compare the efficacy of both treatments.

Methods: This was an open-label, multicentre, single-treatment-arm study in children aged <7 years with a confirmed diagnosis of CF and EPI. After the screening period (approximately 14 days), all patients entered a 3-day assessment period on their usual PERT (standard therapy), followed by the study drug treatment phase (10–14 days; target dose 8000 lipase units/kg bodyweight/day), which included a second 3-day assessment period. The safety and tolerability of both treatments were documented by recording adverse events (AEs). Clinical symptoms (mean daily stool frequency, abdominal pain, stool consistency and flatulence) were monitored and ease of accurate dosing, as judged by caregivers, was reported. Efficacy was determined by comparison of percent stool fat in spot stool samples collected during both 3-day assessment periods.

Results: Of the 19 patients who had informed consent from their parent/ legally acceptable representative, one was withdrawn as a screen failure and was excluded from the safety and efficacy analyses; thus, 18 patients completed the study. The median age (range) was 23 (4–71) months and 13 (72%) were male. During study drug treatment, patients received a mean ± SD dose in lipase units/kg bodyweight/day of 7542±1335 versus 6966 ± 3392 on standard therapy. Overall, nine (50%) patients had at least one treatment-emergent AE (TEAE) whilst receiving either treatment. All TEAEs in this study were reported as mild and none resulted in patient discontinuation. The caregivers had a slight preference for study drug over standard therapy in terms of ease of accurate dosing: six (33.3%) caregivers thought the study drug was easier to dose while only one (5.6%) thought the study drug was harder to dose than standard therapy. Clinical symptom assessment results were similar between treatments. There was no clinically meaningful difference (significance not tested) between study drug and standard therapy in the mean ± SD percent of stool fat: 28.1±9.9 and 27.9 ± 8.9, respectively.

Conclusion: In this study in children aged <7 years with EPI due to CF, the new formulation pancrelipase delayed-release capsules (CREON®) were clinically comparable with standard therapy in terms of safety, tolerability and efficacy.


  1. 1.
    Baker SS. Delayed release pancrelipase for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis. Ther Clin Risk Manag 2008; 4(5): 1079–84PubMedGoogle Scholar
  2. 2.
    Borowitz D, Durie PR, Clarke LL, et al. Gastrointestinal outcomes and confounders in cystic fibrosis. J Pediatr Gastroenterol Nutr 2005; 41(3): 273–85PubMedCrossRefGoogle Scholar
  3. 3.
    Littlewood JM, Wolfe SP, Conway SP. Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatr Pulmonol 2006; 41(1): 35–49PubMedCrossRefGoogle Scholar
  4. 4.
    DiMagno MJ, DiMagno EP. Chronic pancreatitis. Curr Opin Gastroenterol 2006; 22(5): 487–97PubMedGoogle Scholar
  5. 5.
    Layer P, Holtmann G. Pancreatic enzymes in chronic pancreatitis. Int J Pancreatol 1994; 15(1): 1–11PubMedGoogle Scholar
  6. 6.
    Abdel Aziz AM, Lehman GA. Current treatment options for chronic pancreatitis. Curr Treat Options Gastroenterol 2007; 10(5): 355–68PubMedCrossRefGoogle Scholar
  7. 7.
    Goodin B. Nutrition issues in cystic fibrosis. Pract Gastroenterol 2005; 29(5): 76–94Google Scholar
  8. 8.
    Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154(5): 1229–56PubMedGoogle Scholar
  9. 9.
    Stallings VA, Stark LJ, Robinson KA, et al. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 2008; 108(5): 832–9PubMedCrossRefGoogle Scholar
  10. 10.
    FitzSimmons SC, Burkhart GA, Borowitz D, et al. Highdose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997; 336(18): 1283–9PubMedCrossRefGoogle Scholar
  11. 11.
    Borowitz DS, Grand RJ, Durie PR. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. J Pediatr 1995; 127(5): 681–4PubMedCrossRefGoogle Scholar
  12. 12.
    DiMagno EP, Malagelada JR, Go VL, et al. Fate of orally ingested enzymes in pancreatic insufficiency: comparison of two dosage schedules. N Engl J Med 1977; 296(23): 1318–22PubMedCrossRefGoogle Scholar
  13. 13.
    Dutta SK, Rubin J, Harvey J. Comparative evaluation of the therapeutic efficacy of a pH-sensitive enteric coated pancreatic enzyme preparation with conventional pancreatic enzyme therapy in the treatment of exocrine pancreatic insufficiency. Gastroenterology 1983; 84(3): 476–82PubMedGoogle Scholar
  14. 14.
    Halm U, Löser C, Löhr M, et al. A double-blind, randomized, multicentre, crossover study to prove equivalence of pancreatin minimicrospheres versus microspheres in exocrine pancreatic insufficiency. Aliment Pharmacol Ther 1999; 13(7): 951–7PubMedCrossRefGoogle Scholar
  15. 15.
    Meyer JH, Elashoff J, Porter-Fink V, et al. Human postprandial gastric emptying of 1–3-millimeter spheres. Gastroenterology 1988; 94(6): 1315–25PubMedGoogle Scholar
  16. 16.
    Vyas H, Matthew DJ, Milla PJ. A comparison of enteric coated microspheres with enteric coated tablet pancreatic enzyme preparations in cystic fibrosis: a controlled study. Eur J Pediatr 1990; 149(4): 241–3PubMedCrossRefGoogle Scholar
  17. 17.
    Domínguez-Muñoz JE, Birckelbach U, Glasbrenner B, et al. Effect of oral pancreatic enzyme administration on digestive function in healthy subjects: comparison between two enzyme preparations. Aliment Pharmacol Ther 1997; 11(2): 403–8PubMedCrossRefGoogle Scholar
  18. 18.
    Stern RC, Eisenberg JD, Wagener JS, et al. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency. Am J Gastroenterol 2000; 95(8): 1932–8PubMedCrossRefGoogle Scholar
  19. 19.
    Safdi M, Bekal PK, Martin S, et al. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis. Pancreas 2006; 33(2): 156–62PubMedCrossRefGoogle Scholar
  20. 20.
    Colombo C, Fredella C, Russo MC, et al. Efficacy and tolerability of Creon for children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study. Pancreas 2009; 38(6): 693–9PubMedCrossRefGoogle Scholar
  21. 21.
    Munck A, Duhamel JF, Lamireau T, et al. Pancreatic enzyme replacement therapy for young cystic fibrosis patients. J Cyst Fibros 2009; 8(1): 14–8PubMedCrossRefGoogle Scholar
  22. 22.
    U.S.Food and Drug Administration. FDA requires pancreatic extract manufacturers to submit marketing applications, 2004 Apr 27 [online]. Available from URL: [Accessed 2010 Apr 13]
  23. 23.
    Solvay Pharmaceuticals Inc. CREON® (pancrelipase) capsules, delayed-release for oral use [US prescribing information]. Marietta (GA): Solvay Pharmaceuticals Inc., Apr 2009 [online]. Available from URL: [Accessed 2010 Apr 13]Google Scholar
  24. 24.
    Shlieout G, Koerner A, Sczesny F, et al. Pancrelipase delayed-release capsules (CREON®) zero-overfill formulation (to-be-marketed) is pharmaceutically comparable to the current formulation [abstract no. SP-27]. JPEN J Parenter Enteral Nutr 2009; 33(3): 227–8. Plus poster presented at the American Society for Parenteral and Enteral Nutrition (ASPEN) Clinical Nutrition Week; 2009 Feb 1–4; New Orleans (LA)Google Scholar
  25. 25.
    Trapnell BC, Maguiness K, Graff GR, et al. Efficacy and safety of Creon® 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros 2009; 8(6): 370–7PubMedCrossRefGoogle Scholar
  26. 26.
    Graff GR, Maguiness K, McNamara J, et al. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7–11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study. Clin Ther 2010; 32(1): 89–103PubMedCrossRefGoogle Scholar
  27. 27.
    Korpi-Steiner NL, Ward JN, Kumar V, et al. Comparative analysis of fecal fat quantitation via nuclear magnetic resonance spectroscopy (1H NMR) and gravimetry. Clin Chim Acta 2009; 400(1–2): 33–6PubMedCrossRefGoogle Scholar
  28. 28.
    Centers for Disease Control and Prevention. Z-score data files, 2009 Aug 4 [online]. Atlanta (GA): Centers for Disease Control and Prevention. Available from URL: [Accessed 2010 Apr 13]
  29. 29.
    Centers for Disease Control and Prevention. BMI percentile calculator for child and teen [online]. Atlanta (GA): Centers for Disease Control and Prevention. Available from URL: [Accessed 2010 Apr 13]
  30. 30.
    Borowitz D, Robinson KA, Rosenfeld M, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009; 155(6 Suppl.): S73–93PubMedGoogle Scholar
  31. 31.
    Borowitz D, Konstan MW, O’Rourke MS, et al. Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis. J Pediatr Pharmacol Ther 2007; 12: 47–52PubMedGoogle Scholar
  32. 32.
    Wooldridge JL, Heubi JE, Amaro-Galvez R, et al. EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. J Cyst Fibros 2009; 8(6): 405–17PubMedCrossRefGoogle Scholar
  33. 33.
    Carroccio A, Pardo F, Montalto G, et al. Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy: a long-term study in cystic fibrosis. Dig Dis Sci 1992; 37(9): 1441–6PubMedCrossRefGoogle Scholar
  34. 34.
    Kalivianakis M, Minich DM, Bijleveld CM, et al. Fat malabsorption in cystic fibrosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long-chain fatty acids. Am J Clin Nutr 1999; 69(1): 127–34PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Gavin R. Graff
    • 1
  • John McNamara
    • 2
  • James Royall
    • 3
  • Steven Caras
    • 4
  • Kristin Forssmann
    • 5
  1. 1.Penn State Milton S. Hershey Medical CenterPenn State Medical School, Department of PediatricsHersheyUSA
  2. 2.Children’s Hospitals and Clinics of MinnesotaMinneapolisUSA
  3. 3.University of Oklahoma Health Sciences CenterOklahoma CityUSA
  4. 4.Solvay Pharmaceuticals, Inc. (now part of Abbott)MariettaUSA
  5. 5.Solvay Pharmaceuticals GmbH (now part of Abbott)HannoverGermany

Personalised recommendations